Ocena ekspresji receptora estrogenowego, progesteronowego i receptora HER2 w wybranych nowotworach złośliwych ślinianek
Journal Title: Otolaryngologia Polska - Year 2013, Vol 67, Issue 5
Abstract
Introduction: The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor. Aim: The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies. Materials and methods: Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed. Results: The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor – salivary duct carcinoma. Conclusion: HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
Authors and Affiliations
Wojciech Golusiński, Anna Wegner, Paweł Trzeciak, Marcin Sówka, Andrzej Kopczyński, Małgorzata Bromboszcz
Keywords
Related Articles
- EP ID EP52211
- DOI -
- Views 101
- Downloads 0
The influence of nasal flow aerodynamics on the nasal physiology
The ability of the human nose to warm and humidify the respiratory air is important to maintaining the internal environment of the lungs, since ambient air is conditioned to nearly alveolar conditions (body temperature a...
Krwawienie pierwszym objawem raka migdałka podniebiennego
The authors present the case of the patient suffering from recurrent bleeding from the palatine tonsil. A visual and tactile examination did not reveal any alteration to the tonsil. Following three recurrent bleeding epi...
Ocena ośrodkowych procesów słuchowych u dzieci ze specyficznymi zaburzeniami rozwoju mowy i języka
Specyficzne zaburzenia rozwoju mowy i języka (Specific Language Impairment – SLI) dotykają ok. 7–15% dzieci w wieku szkolnym. Według obecnie stosowanych kryteriów rozpoznania przyjmuje się, że grupa tych dzieci ma prawid...
Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis
Differential diagnosis of neck tumours puts precedence on diagnosing neoplastic lesions. In the case of neck tumours, these are unfortunately late signs , but in patients with a primary neoplastic focus within the head a...
Ubytki słuchu w chorobach neurologicznych
Choroby neurologiczne objawiają się w sposób różnorodny i złożony. Ogniskowe objawy neurologiczne, takie jak niedowłady, afazja, ubytki w polu widzenia, którym bardzo często towarzyszy pogorszenie stanu pacjenta sprawiaj...